with immediately deliveryParoxetine 110429-35-1 in stockfactory GMP CAS NO.110429-35-1
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Product Details
Keywords
- Paroxetine 110429-35-1 with immediately delivery
- Paroxetine 110429-35-1 in stock
- factory GMP Paroxetine 110429-35-1
Quick Details
- ProName: with immediately deliveryParoxetine 11...
- CasNo: 110429-35-1
- Molecular Formula: C19H20FNO3·HCI·1/2H2O
- Appearance: White or almost white solid
- Application: Anti-Depression
- DeliveryTime: 10 days after ordering
- PackAge: Two-layer LDPE bag and All Paper Drum
- Port: Any port in China
- ProductionCapacity: 50 Metric Ton/Year
- Purity: 98.5%-102.0%
- Storage: Below 30℃
- Transportation: as per request
- LimitNum: 1 Kilogram
Superiority
with immediately deliveryParoxetine 110429-35-1 in stockfactory GMP
Quality:
Details
Paroxetine(1μMand10μM)distinctlyrestrainsTcellmigrationinducedbyCX3CL1throughinhibitingGRK2.ParoxetineinhibitsGRK2inducedactivationofERK.Paroxetine(10μM)reducespro-inflammatorycytokinesinLPS-stimulatedBV2cells.Paroxetine(0-5μM)leadstoadose-dependentinhibitiononLPS-inducedproductionofTNF-αandIL-1βinBV2cells.Paroxetinealsoinhibitslipopolysaccharide(LPS)inducednitricoxide(NO)productionandinduciblenitricoxidesynthase(iNOS)expressioninBV2cells.Paroxetine(5μM)blocksLPSinducedJNKactivationandattenuatesbaselineERK1/2activityinBV2cells.Paroxetinerelievesmicroglia-mediatedneurotoxicity,andsuppressesLPS-stimulatedpro-inflammatorycytokinesandNOinprimarymicroglialcells.
ParoxetinetreatmentobviouslyattenuatesthesymptomsofCIArats.ParoxetinetreatmentclearlypreventsthehistologicaldamageofjointsandalleviatesTcellsinfiltrationintosynovialtissue.ParoxetinerevealsastrongeffectoninhibitingCX3CL1productioninsynovialtissues.Paroxetine(20mg/kg/day)reducesthemyocytecrosssectionalareainratandROSformationintheremotemyocardium.Paroxetinereducesthesusceptibilitytoventriculartachycardia.ParoxetinetreatmentfollowingMIdecreasesLVremodelingandsusceptibilitytoarrhythmias,probablybyreducingROSformation.InCCIparoxetine-treatedgroup,paroxetine(10mg/kg,i.p.)produceshyperalgesiaatdays7and10(P<0.01),butadecreaseinpainbehaviorisseenatday14.Moreover,paroxetine(10mg/kg)significantlyattenuatestactilehypersensitivitywhencomparedtoCCIvehicle-treatedgroup.